Hu8H9 (B7-H3) - Y-mAbs Therapeutics

Drug Profile

Hu8H9 (B7-H3) - Y-mAbs Therapeutics

Latest Information Update: 14 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Y-mAbs Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action CD antigen modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Ovarian cancer

Most Recent Events

  • 14 Sep 2016 Antibody 8H9 is covered by patent protection in USA (Y-mAbs therapeutics website, September 2016)
  • 09 Sep 2016 Preclinical trials in Ovarian cancer (In adults) in USA (Intraperitoneal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top